Premium
Integrin α v β 3 ‐targeted cancer therapy
Author(s) -
Liu Zhaofei,
Wang Fan,
Chen Xiaoyuan
Publication year - 2008
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.20265
Subject(s) - integrin , angiogenesis , cancer research , metastasis , alpha (finance) , peptidomimetic , cancer , immunology , biology , medicine , microbiology and biotechnology , receptor , biochemistry , peptide , construct validity , nursing , patient satisfaction
Anti‐angiogenesis is a promising strategy for the treatment of cancer. Integrins, consisting of two noncovalently bound transmembrane α and β subunits, are an important molecular family involved in tumor angiogenesis. The blockade of integrin signaling has been demonstrated to be efficient to inhibit tumor growth, angiogenesis, and metastasis. Among all the integrins, α v β 3 seems to be the most important one during tumor angiogenesis. The inhibition of integrin α v β 3 signaling with antibodies, peptides, peptidomimetics, and other antagonists has great potential in the treatment of cancer. In addition, integrin α v β 3 is highly expressed on activated endothelial cells, new‐born vessels as well as some tumor cells, but is not present in resting endothelial cells and most normal organ systems, making it a suitable target for anti‐angiogenic therapy. In this article we will review the role of integrin α v β 3 in angiogenesis, present recent progress in the use of integrin α v β 3 antagonists and integrin‐targeted delivery systems as potential cancer therapeutics, and discuss future perspectives. Drug Dev Res 69:329–339, 2008. © 2008 Wiley‐Liss, Inc.